2016 American Transplant Congress Archives - Page 31 of 180

Ibrutinib Suppresses Alloantibody Responses in A Mouse Model of Allosensitization: A Preliminary Report.

G. Wu, I. Kim, N.-N. Chai, A. Klein, S. Jordan.
Ideal Outcome After Liver Transplantation: An Exploratory Study Using Machine Learning Analyses to Leverage Long-Term Registry Data from Studies in Pediatric Liver Transplantation (SPLIT).

E. Hsu,¹ M. Shaffer,^1,2 R. Anand,³ V. Ng,⁴ J. Bucuvalas.⁵
Identification of Biomarkers for Progressive Fibrosis in Renal Transplant Patients Using Novel Chemical Imaging Approaches.

V. Varma,¹ A. Kajdacsy-Balla,¹ S. Akkina,² S. Setty,¹ M. Walsh.¹
Identification of Donor HLA-Specific Antibodies as a Risk Factor for Graft Dysfunction and Failure Following BK Virus Associated Nephropathy.

E. Abuhelaiqa, S. Salvatore, J. Lee, J. Lee, V. Sharma, T. Muthukumar, S. Seshan, M. Suthanthiran, D. Dadhania.
Identification of MicroRNAs in EBV⁺ B Cell Lymphomas and Secreted Exosomes.

V. Kaul, A. Harris-Arnold, C. Esquivel, O. Martinez, S. Krams.
Identifying Social Barriers to Health Literacy in ESRD Patients Undergoing Kidney Transplant Evaluation.

K. Leick,¹ J. Jones,¹ S. Witte,² L. Hunsicker,³ Z. Stewart.¹
IFN-γ and Contact-Dependent Cytotoxicity Are Rate-Limiting for NK Cells in a Model of Antibody-Mediated Chronic Rejection.

C. Lin,¹ R. Plenter,¹ R. Gill.²
IFTA Is Linked to Urinary Microbiome Changes.

B. Modena, R. Milam, F. Harrison, S. Kurian, D. Salomon, A. Kirk.
IgG Dilutions, Subclasses, C1q, and IgM: Determining Relevant Testing for De Novo DSA and Outcome Prediction.

M. Everly,¹ L. Rebellato,² C. Haisch,² K. Briley,² P. Bolin,² S. Kendrick,³ C. Morgan,² A. Maldonado,⁴ A. Nguyen,¹ P. Terasaki.¹
IgM Donor Specific Antibodies Are Frequently Associated with C1q-binding DnDSA in Renal Transplant Recipients.

J. Bamoulid,³ A. Roodenburg,⁴ O. Staeck,¹ C. Schoenemann,² N. Lachmann,² K. Budde.¹
IgM Treatment Successfully Prevents Type 1 Diabetes by Dysregulation of Pancreatic MicroRNAs with Immunomodulatory Roles.

P. Chhabra, R. Gehrau, V. Mas, D. Bower, D. Maluf, K. Brayman.
IL-10 Expression of In Vitro Activated B Cells as A Biomarker for B Cell Tolerance.

T. Oura, K. Hotta, K. Crisalli, B. Cosimi, T. Kawai.
IL-17-Producing CCR6⁺CD4⁺ Th17 Cells Drive Intestinal Allograft Rejection in Humans.

J. Kaiser, C. Cosentino, A. Shukla, C. Desai, R. Girlanda, J. Hawksworth, C. Matsumoto, M. Zasloff, T. Fishbein, A. Kroemer.
IL-17A Preactivated Mesenchymal Stem Cells (MSC-17) Are Enriched for Genes Involved in T Cell Chemotaxis to Mediate Superior Immunosuppression.

K. Sivanathan,^1,2,3 D. Rojas-Canales,^1,2 S. Gronthos,⁴ S. Grey,⁵ P. Coates.^1,2,3
IL-2 Therapy Restores the Impaired Function of Regulatory T Cells Induced by Calcineurin Inhibitors in Liver Transplantation.

G. Whitehouse, E. Gray, S. Mastoridis, E. Kodela, A. Sanchez-Fueyo, M. Martinez-Llordella.
IL2 and IL-15 Rescue TEMRA CD8 T Cells from Mitochondrial Dysfunction Associated Senescence Through a p38MAPK Dependent Pathway and Foster Their Pathogenic Potential.

G. Tilly,^1,2 M. Yap,^1,2 M. Giral,^1,2,3 C. Pecqueur,⁴ S. Brouard,^1,3 N. Degauque.^1,3
Imaging Cell Biology In Vivo with Intravital-Microscopy.

T. Ueno,¹ M. Yeung,¹ N. Igarashi,³ T. Yokoyama,² Y. Kihara,² O. Konno,² Y. Nakamura,² H. Iwamoto,² T. Ikeda,³ M. McGrath,¹ M. Sayegh,¹ A. Chandraker.¹
Immediate Introduction of Everolimus Does Not Affect Wound Healing and Delayed Graft Function in Kidney Transplant Recipients: 3-Months Results from NEVERWOUND Study.

M. Carmellini,¹ P. Todeschini,² A. Secchi,³ S. Sandrini,⁴ E. Minetti,⁵ L. Furian,⁶ G. Spagnoletti,⁷ F. Pisani,⁸ G. Piredda,⁹ G. Cappelli,¹⁰ G. Tisone.¹¹
Imminent Death Donation: Potential Effects on Organ Donation Numbers and Clinical Outcomes.

V. Potluri,¹ S. Nazarian,² M. Levine,² P. Reese.³
Immune Response to BK Virus in Renal Transplant Recipients.

D. DeWolfe,¹ J. Gandhi,¹ M. Mackenzie,¹ T. Broge,¹ E. Bord,¹ D. Mandelbrot,¹ R. Viscidi,² F. Cardarelli,¹ M. Pavlakis,¹ C. Tan.¹
Immune Tolerance Monitoring in Renal Allograft Tolerance Induced by Transient Mixed Chimerism in Nonhuman Primates and Humans.

K. Hotta, T. Oura, K. Crisalli, D. Sachs, B. Cosim, T. Kawai.
Immunogenic HLA-DR Eplet Mismatches as Predictors of Transplant Glomerulopathy.

D. Blum,¹ K. Tinckam,² M. Marrari,³ J. Kim,² R. Sapir-Pichhadze.¹
Immunologic Basis for Immunocloaking.

L. Brasile,¹ K. Kizjakina,¹ N. Henry,¹ B. Stubenitsky.²
Immunological Ageing-Related Expansion of Highly Differentiated CD4⁺CD28null T Cells Is Associated with a Lower Risk for Early Acute Rejection After Renal Transplantation.

B. Dedeoglu, R. Meijers, M. Klepper, D. Hesselink, C. Baan, N. Litjens, M. Betjes.
Immunosuppressive Actions of CLI95 and CORM401 on TLR4 in Renal Ischemia Reperfusion Injury.

P. Luke,^1,2,5 G. Cepinskas,^1,4 H. Alharbi,^3,5 A. Haig,^3,5 R. Bhattacharjee.^1,2,5
Impact of Allograft Dysfunction and Early Low Grade Proteinuria on Survival in Expanded Criteria Donor Kidney Transplant Recipients.

V. López, M. Cabello, P. Ruiz, C. Jironda, D. Burgos, M. González-Molina, D. Hernández.
Impact of Angiotensin II Type I Receptor Antibody Positivity in Highly-HLA Sensitized (HS) Patients Transplanted After Desensitization (DES).

A. Vo,¹ C. Boutsicaris,¹ X. Zhang,² N. Reinsmoen,² J. Choi,¹ S. Jordan.¹
Impact of BKV Subtype Distribution on BKV Nephropathy, Viremia, and Renal Outcome in Patients After Renal Transplantation.

S. Anke,¹ L. Silvia,¹ H. Hermann,¹ H. Albert,² S. Corinna.²
Impact of C3d and C1q-Binding DSA Detected Long-Term After Kidney Transplantation.

M. Crespo,^1,2 D. Redondo,^1,2 C. Garcia,³ J. Gimeno,⁴ M. Perez,^1,2 M. Mir,¹ J. Hernandez,³ J. Yelamos,² A. Faura,^1,2 J. Pascual.^1,2
Impact of Cold Ischemia Time on the Outcomes of Kidneys with KDPI >85%: Mate Kidney Analysis.

M. Sampaio, B. Chopra, K. Sureshkumar.
Impact of CXCR4/CXCL12 Blockade on Normal Plasma Cells In Vivo.

K. Bonner, N. Moore, M. Moreno Gonzales, M. Stegall.
Impact of Delayed Graft Function Varies by Demographic and Clinical Characteristics in Deceased Donor Kidney Transplantation.

C. Liao, A. Massie, S. Bae, A. Muzaale, D. Segev.
Impact of Donor AKI on Outcome Following High KDPI Deceased Donor Kidney Transplantation.

D. Haakinson,¹ I. Qaqish,² M. Smith,³ H. Khamash,² K. Reddy,¹ R. Heilman.²
Impact of Donor Specific Antibodies on Cardiac Allograft Vasculopathy.

A. Vu,¹ A. Althouse,² A. Zeevi,³ J. Teuteberg,² M. Shullo.²
Impact of Donor-Recipient Relationship on Development of CKD.

A. Matas, D. Vock, H. Ibrahim.
Impact of Early Acute Rejection (AR) on Pancreas Transplant (PT) Outcomes.

V. Kirchner, T. Dunn, A. Kukla, R. Kandaswamy, E. Finger.
Impact of Early Allograft Dysfunction (EAD) and Its Components on Patient Survival Following Liver Transplantation (LT): Long-Term Outcomes Up to 10 Years.

B. Ekser, R. Mangus, J. Fridell, C. Kubal, J. Davis, J. Salisbury, T. Salisbury, S. Nagaraju, P. Mihaylov, A. Tector.
Impact of Early Calcineurin Inhibitor Withdrawal on Renal Function and Urinary Protein Excretion: 24 Month Analyses of the ELEVATE Study.

J. de Fijter,¹ H. Holdaas,¹ M. Seelen,¹ S. Sundar,¹ F. Bemelman,¹ P. Lopez,² J. Aguilar,² P. Bernhardt,² Z. Wang,³ J. Cruzado,¹ M. van der Giet.¹
Impact of Early Hospital Readmission Following Simultaneous Pancreas Kidney Transplantation.

E. King, L. Kucirka, M. McAdams-DeMarco, M. Bowring, A. Massie, D. Segev.
Impact of Early Hospital Readmissions After Kidney Transplantation on Graft Function.

I.-K. Kim, M. Ju, S. Son.
Impact of Early Red Blood Cell Transfusion After Kidney Transplantation on De Novo HLA Sensitization in the Setting of Antithymocyte Globulin Induction.

T. Jouve,^1,2 G. Rigault,^1,2 B. Janbon,¹ R. Tetaz,¹ N. Terrier,¹ D. Masson,³ L. Rostaing,^1,2 P. Malvezzi.¹
Impact of Ethnicity on Tacrolimus Trough/Dose Ratios Following Solid Organ Transplantation.

A. Santeusanio, A. Owusu-Obeng, J. Jeff.
Impact of Everolimus and Low-Dose Ciclosporin on Cytomegalovirus Replication and Disease in Pediatric Renal Transplantation.

B. Höcker,¹ S. Zencke,¹ L. Pape,² K. Krupka,¹ L. Kösters,¹ A. Fichtner,¹ L. Dello Strologo,² I. Guzzo,² R. Topaloglu,² B. Kranz,² J. König,² M. Bald,² N. Webb,² A. Noyan,² H. Dursun,² S. Marks,² Z. Ozcakar,² F. Thiel,² H. Billing,² M. Pohl,² H. Fehrenbach,² P. Schnitzler,¹ T. Bruckner,¹ L. Weber,² R. Feneberg,² T. Ahlenstiehl-Grunow,² B. Tönshoff.¹
Impact of HLA-DR Compatibility on Efficacy Outcomes and Renal Function in Kidney Transplant Recipients Following Early Switch from Calcineurin Inhibitor to Everolimus: Subanalysis from the ELEVATE Study.

J. Cruzado, H. Holdaas, P. Lopez, J. Aguilar, G. Dong, F. Claas, W. Arns, M. van der Giet, J. de Fijter.
Impact of Ideal Body Weight vs. Actual Body Weight for the Prediction of Small for Size Syndrome and Graft Loss After Living Donor Liver Transplantation.

M. Dib, N. Goldaracena, A. Barbas, M. Marquez, N. Alotaiby, G. Sapisochin, M. Cattral, L. Lilly, I. McGilvray, E. Renner, P. Greig, A. Ghanekar, N. Selzner, M. Selzner, D. Grant.
Impact of Immunosuppressants on Inducing Regulatory T Cells in Human Allo-Immune Responses.

Y. Tanaka, H. Ohdan.
Impact of Induction Therapy on Cardiovascular Events in Kidney Transplant Recipients.

S. Sandal,^1,2 S. Bae,² A. Massie,² M. Cantarovich,¹ D. Segev.²
Impact of Left Ventricular Diastolic Dysfunction on Patients Being Evaluated for Liver Transplantation.

K. Forde,¹ R. McLean,¹ W. O'Donnell,¹ K. Krok,² M. Patel,¹ G. Lin,³ J. Oh,³ M. Krowka,³ M. Fallon,⁴ S. Kawut.¹
Impact of Low Dose Tacrolimus with Everolimus Regimen on Renal Pathology and T-Regulatory Cells in Kidney Transplant.

A. Shetty,¹ T. Opas,¹ J. Mathew,¹ V. Mas,² J. Leventhal,¹ N. Sustento-Reodica,¹ L. Gallon.¹
Impact of Machine Perfusion on Long-Term Kidney Transplant Outcomes.

S. Sandal,^1,2 X. Luo,² A. Massie,² M. Cantarovich,¹ D. Segev.²
Impact of Mixed Xenogeneic Chimerism on Human B Cell Response to Pig Antigens.

H. Li, S. Shao, P. Vishwasrao, M. Holzl, M. Sykes.
Impact of Mixed Xenogeneic Porcine Hematopoietic Chimerism on Human NK Cell Recognition in a Humanized Mouse Model.

H. Li,¹ P. Vishwasrao,^1,2 M. Holzl,¹ S. Chen,¹ G. Choi,^2,3 G. Zhao,¹ M. Sykes.¹
Impact of Morbid Obesity on Breakthrough CMV Infection in Kidney Transplant Recipients.

S. Strout, N. Pilch, T. Veasey, R. Miller, J. Fleming, H. Meadows, C. Mardis, B. Mardis, P. Baliga, K. Chavin, D. Taber.
Impact of New Kidney Allocation System on Transplant Rates for Highly Sensitized Patients-Center Specific Study.

X. Zhang, M. Naim, A. Vo, S. Jordan, N. Reinsmoen.
Impact of Pre-Existing Comorbidities on Long-Term Patient and Graft Survival in Kidney Transplant Recipients.

F. Halleck, D. Khadzhynov, L. Lehner, E. Schrezenmeier, M. Duerr, A. Kleinsteuber, K. Budde, O. Staeck.
Impact of Preformed Anti-HLA Antibodies in the Outcomes of Kidney Transplantation.

S. Santos,¹ J. Malheiro,¹ M. Costa,² A. Campos,¹ S. Pedroso,¹ M. Almeida,¹ L. Martins,¹ L. Dias,¹ C. Henriques,¹ A. Cabrita.¹
Impact of Preoperative Body Composition on Outcomes After Living Donor Liver Transplantation.

Y. Hamaguchi, T. Kaido, A. Kobayashi, S. Okumura, S. Yagi, H. Okajima, S. Uemoto.
Impact of Pretransplant Non-Donor-Specific HLA Immunization: Mainly Class 1 Immunization Leads to Poor Immunologic Outcome and Graft Loss.

O. Staeck, F. Halleck, A. Staeck, L. Lehner, M. Duerr, E. Schrezenmeier, K. Budde, D. Khadzhynov.
Impact of Proximity MELD/PELD Points on Liver Redistricting Scenarios.

S. Gentry,^1,2 J. Pyke,¹ D. Schladt,¹ J. Zeglin,¹ W. Kim,³ J. Lake,⁴ R. Hirose,⁵ D. Mulligan,⁶ A. Israni.¹
Impact of Sarcopenia in Overweight/Obese Recipients on the Outcomes After Adult Living Donor Liver Transplantation.

A. Hammad,^1,2 Y. Hamaguchi,² S. Okumura,² A. Kobayashi,² S. Yagi,² S. Uemoto,² T. Kaido.²
Impact of Simultaneous Pancreas-Kidney Transplantation versus Kidney Transplant Alone on Patient and Graft Survival in Type 2 Diabetics with Elevated BMI.

S. Singh,^1,2 S. Kim.^1,2,3,4
Impact of Social Support on Feelings of Powerlessness and Attitudes Towards the Kidney Transplant in Long-Term Inner City Recipients.

S. Wu, A. Brar, M. Markell.
Impact of the Kidney Allocation System with Deceased Donor Kidney Transplantation: A Single Center Experience.

A. Agarwal, W. Ally, D. Maluf, S. Pelletier, K. Brayman.
Impact of the Kidney Allocation System with Deceased Donor Kidney Utilization at the DSA Level.

W. Ally,² C. Saunders,¹ K. Brayman,² A. Agarwal.²
Impact of the National Overdose Death Epidemic on the Deceased-Donor Pool.

M. Bowring, A. Massie, L. Kucirka, E. Chow, M. Sulkowski, D. Segev, C. Durand.
Impact of the New Kidney Allocation System (KAS) on Transplant Rates & Outcomes in Broadly-HLA Sensitized (HS) Patients Transplanted After Desensitization (DES).

A. Vo,¹ X. Zhang,² S. Williamson,¹ K. Myers,¹ N. Reinsmoen,² J. Choi,¹ J. Kahwaji,¹ A. Peng,¹ R. Villicana,¹ S. Jordan.¹
Impact of the New Kidney Allocation System on Highly Sensitized Patients: Single Center Report.

A. Mattiazzi,¹ W. Kupin,¹ D. Roth,¹ L. Chen,² G. Burke,² G. Ciancio,² P. Ruiz,² R. Vianna,² G. Guerra.¹
Impact of Transfusion Requirements on Likelihood of Heart Transplantation After Total Artificial Heart.

J. Cook,¹ L. Kang,¹ M. Flattery,² I. Tchoukina.²
Impact on Renal Function of Stepwise Withdrawal of Tacrolimus Combined with Everolimus and EC-MPS vs Standard Treatment Combining Tacrolimus and EC-MPS in De Novo Liver Transplant Recipients: Results of the SIMCER Study.

F. Saliba,¹ C. Duvoux,² S. Dharancy,³ J. Dumortier,⁴ Y. Calmus,⁵ F. Di Giambattista,⁶ F. Conti.⁵
Impact on Wound Healing Events After Early Conversion to Everolimus in De Novo Renal Transplant Recipients: 24-Month Results from the Randomized ELEVATE Study.

B. Nashan,¹ M. van der Giet,¹ H. Holdaas,¹ M. Zeier,¹ J. Pascual,¹ Y. Avihingsanon,¹ P. Lopez,² J. Aguilar-Sanchez,² J. Kochuparampil,² Z. Wang,³ J. Cruzado,¹ J. De Fijter.¹
Impaired Outcome of Kidney Transplants from Donors with Acute Kidney Injury.

K. Schuette-Nuetgen,¹ G. Thölking,¹ H. Pavenstädt,¹ S. Ehlert,¹ B. Suwelack,¹ D. Palmes,² R. Bahde,² S. Reuter.¹
Impediments to Timely Listing for HIV+ Patients Being Evaluated for Kidney Transplantation.

D. Lee,¹ A. Aldea,¹ M. Harhay,² S. Akshay,² G. Malat,³ N. Law,¹ S. DeBellis,² T. Bias,¹ S. Boyle,² K. Ranganna,² A. Doyle.²
Implementation of a Risk Stratified Approach for Prevention of Hepatitis B Reactivation Post Kidney Transplant.

M. Cote,¹ M. Pavlakis,² J. Ethridge,¹ C. Currier,² M. Curry,² E. Khankin,² F. Cardarelli,² K. Richards,^1,2 C. Rogers.^1,2
Implementation of Telehealth Is Associated with Improved Timeliness of Kidney Transplant Waitlist Evaluation at a VA Center.

R. Forbes,^1,2 K. Kummerow Broman,^1,2 T. Johnson,² D. Rybacki,² M. Hagemann,² A. Hannah-Gillis,² I. Feurer,¹ D. Hale.^1,2
Implications of Subclinical Borderline Acute Cellular Rejection Detected in Protocol Biopsies on Graft Outcomes.

Z. Zaky,¹ C. Yu,¹ N. Elfadawy,² A. Chiesa-Vottero,¹ L. Herlitz,¹ S. Flechner,¹ E. Poggio.¹
Implicit Bias in Dialysis Providers' Transplant Education Practices for Low-Income and Racial/Ethnic Minority Patients.

C. Gonzalez,^1,2 A.-M. McSorley,¹ J. Peipert,¹ K. Norris,¹ C. Goalby,¹ L. Peace,³ P. Lutz,³ A. Waterman.¹
Improved Health Related Quality of Life Also in Older Recipients Following Kidney Transplantation.

K. Lønning,¹ K. Heldal,^2,3 T. Bernklev,^2,3 M. Andersen,^1,4 A. Hartmann,^1,3 N. Von der Lippe,³ A. Reisæter,¹ K. Midtvedt.¹
Improved Regeneration of the Remnant Liver After Extended Hepatectomy or Partial Liver Transplantation by Pharmacologic Mobilization of Endogenous Stem Cells in Rats.

M. Chen, R. Zhai, L. Qi, A. Cameron, B. Philosophe, Z. Sun.
Improving Donor Comfort: Perioperative Dexamethasone Decreases Nausea, Vomiting, and Pain After Laparoscopic Donor Nephrectomy.

S. Yamanaga,^1,2 A. Posselt,¹ C. Freise,¹ S.-M. Kang.¹
Improving Kidney Allocation System with Higher Resolution.

M. Cusick, J. Friedewald, K. Haarberg, J. Leventhal, A. Tambur.
Improving the Efficiency, Safety and Cost of Evaluating Living Donor Liver Candidates Using Single Sequence MRI.

M. Schilsky,^1,2 K. Cartiera,¹ S. Boga,¹ S. Schilsky,³ S. Emre,¹ D. Mulligan,¹ J. Weinreb,¹ G. Israel.¹
In Situ Aortic Flush with Lactated Ringer's (LR) Solution During Donation After Brain Death (DBD) Organ Procurement Provides Similar Outcomes and Significantly Decreases Costs in Kidney and Liver Transplantation Compared to Standard Preservation Solutions.

S. Rudich, P. Lange.
In Their Own Words: Living Kidney Donors Who Develop Kidney Failure.

L. Ross,¹ C. Halverson,² J. Wang,¹ M. Poulson,³ J. Karlin,⁴ M. Crowley-Matoka.⁵
In Vitro and In Vivo Characterization of Human Hematopoietic Chimeric Cells – A Novel Approach for Tolerance Induction in Transplantation.

M. Siemionow, E. Tfaily, M. Cyran, R. Gendek, M. Strojny, E. Szilagyi, J. Cwykiel.
In Vitro Induction of T Regulatory Cells by Multipotent Adult Progenitor Cells.

S. Stubblefield, N. Williams, A. Ting.
In Vitro Reactivity of CD4⁺ T Cells Subsets from Hosts with Antigen Specific Transplant Tolerance Mediated by CD4⁺CD25⁺T Cells.

B. Hall, C. Robinson, K. Plain, N. Verma, G. Tran, N. Carter, M. Nomura, R. Boyd, S. Hodgkinson.
Incidence & Impact of De Novo DSA (dnDSA) Formation on Transplant Outcomes in HLA-Sensitized (HS) Patients Transplanted After IVG+Rituximab Desensitization (DES).

A. Vo,¹ J. Choi,¹ J. Kahwaji,¹ J. Mirocha,² A. Peng,¹ R. Villicana,¹ S. Jordan.¹
Incidence and Factors Associated with De Novo DSA After BK Viremia in Renal Transplant Recipients.

S. Patel, S. Kuten, R. Knight, D. Nguyen, E. Graviss, A. Gaber.
Incidence and Indications for Pancreatectomy After Late Pancreas Allograft Failure.

S. Parajuli, A. Djamali, B. Astor, H. Sollinger, D. Kaufman, R. Redfield, J. Odorico, D. Mandelbrot.
Incidence and Renal Consequences of Type 2 Diabetes Mellitus in Kidney Donors.

H. Ibrahim, A. Matas, D. Berglund, S. Reule, A. Kukla, N. Issa, R. Spong, R. Foley.
Incidence of and Risk Assessment for Adverse Cardiovascular Outcomes Following Liver Transplantation: A Systematic Review.

M. Konerman,¹ D. Fritze,² R. Weinberg,³ E. Spengler,¹ C. Sonnenday,² P. Sharma.¹
Incidence of Anxiety Following Live Kidney Donation.

J. Leanza, A. Massie, D. Segev.
Incidence of Depression Following Live Kidney Donation.

J. Leanza,¹ S. Anjum,¹ L. Fahmy,¹ S. Bae,¹ R. Reed,² J. Locke,² A. Massie,¹ D. Segev.¹
Incidence of Infectious Disease and Malignancies After Rituximab Therapy in Kidney-Transplant Recipients.

E. Schrezenmeier,¹ T. Doerner,² O. Staeck,¹ K. Budde,¹ F. Halleck.¹
Incidence of Polyoma Virus Associated Nephropathy in a Single Transplant Center Employing a Reduction of Immunosuppression at a Lower Threshold of BK Viremia.

M. Azar, A. Valika, D. Banach, I. Hall, M. Malinis.
Incidence of Post-Transplant Cardiovascular Disease After Pediatric Kidney Transplantation.

O. Serrano,¹ A. Bangdiwala,² D. Vock,² W. Payne,¹ T. Dunn,¹ S. Chinnakotla,¹ E. Finger,¹ R. Kandaswamy,¹ T. Pruett,¹ A. Matas,¹ B. Chavers.³
Incidence of Post-Transplant Lymphoproliferative Disorder in First, Kidney-Only Transplant Recipients Remains Stable.

J. Molony,¹ Y. Peng,¹ N. Baker,² U. Meier-Kriesche,³ J. Snyder.¹
Incidence of Post-Transplant Malignancy (PTM) After Pediatric Kidney Transplantation (PKTx).

O. Serrano,¹ A. Bangdiwala,² D. Vock,² W. Payne,¹ T. Dunn,¹ S. Chinnakotla,¹ E. Finger,¹ R. Kandaswamy,¹ T. Pruett,¹ A. Matas,¹ B. Chavers.³
Incidence of Viral Infections in HLA-Sensitized Patients (HS Pts) Desensitized with IVIG + Rituximab (DES) Compared to Non-HS Pts Receiving Standard Immunosuppression.

S. Jordan, J. Choi, B. Shin, J. Kahwaji, S. Ge, D. Thomas, A. Vo, O. Galera, R. Villicana, A. Peng, M. Toyoda.
Incidence, Risk Factors and Treatment of Incisional Hernia After Kidney Transplantation – An Analysis of 1564 Consecutive Patients.

L. Ooms,¹ J. Verhelst,¹ J. Jeekel,² J. IJzermans,¹ J. Lange,¹ T. Terkivatan.¹
Incidence, Risk Factors, and Outcomes of Delayed Graft Function in Deceased Donor Kidney Transplantation in a Brazilian Center.

A. Ribeiro,¹ M. Helfer,² O. Costa,² A. Viccari,¹ R. Manfro.^1,2
Inclusion of Human Tissue Factor Pathway Inhibitor or Thrombomodulin Transgenes Attenuates Critical Consumptive Thrombocytopenia in Cardiac Xenotransplantation.

J. Chan,¹ A. Singh,¹ P. Corcoran,¹ M. Thomas III,² B. Lewis,² D. Ayares,³ K. Horvath,¹ M. Mohiuddin.¹
Inconsistent HLA Antibody Reactivity Detected with Different Solid-Phase Assays.

A. Jaramillo,¹ L. Nelson,¹ Y. Desmarteau,¹ B. Labuda,² K. Barrios,² J. Lunz,² R. Heilman,³ M. Pando.¹
Increased Access to Transplantation of Highly Sensitized Patients Facilitated by the New Kidney Allocation System.

A. Colovai, M. Ajaimy, C. Savchik, S. Chan, P. Masiakos, J. Rocca, E. Akalin.
Increased Frequency of Post-Recovery Liver Reallocation: The Law of Unintended Consequences?

J. Orlowski, C. Muse, J. Whaley, R. Squires.
Increased Gene Expression of TGF-β in Peripheral Blood Mononuclear Cells from Renal Transplant Patients with Polyomavirus BK Viremi.

W. Yin,¹ M. Lu.²
Increased Incidence of Clostridium difficile Infections with Proton Pump Inhibitor Use Post-Kidney Transplant.

M. Spinner,¹ K. Patel,¹ E. Neuner,¹ B. Stephany.²
Increased Utilization of High Risk Deceased Donors with Share 35 Does Not Affect Outcomes in Liver Transplantation.

M. Boktour, A. Saharia, D. Victor, S. Gordon-Burroughs, C. Mobley, R. McFadden, V. Ankoma-Sey, J. Galati, A. Gaber, H. Monsour, R. Ghobrial.
Increased Waitlist Death and Removal in Pediatric Liver Transplant Recipients Denied Exception Requests.

H. Braun,³ J. Dodge,² S. Rhee,¹ J. Roberts,² E. Perito.¹
Increasing Tacrolimus Time-in-Therapeutic Range Is Associated with Less Cellular Rejection in Lung Transplant Recipients.

C. Ensor, K. Harrigan, R. Venkataramanan, M. Morrell, C. Moore, J. Hayanga, M. Crespo, J. DCunha, A. Zeevi, J. McDyer.
Increasing Volume and Improved Survival in Solid Organ Transplantation for Amyloidosis – An Analysis of the UNOS Database.

J. Jaramillo,¹ J. Stehlik,¹ J. Fang,¹ R. Al-Dulaimi,¹ E. Gilbert,¹ S. Drakos,¹ O. Wever-Pinzon,¹ C. Selzman,¹ S. McKellar,¹ T. Kovacsovics,² J. Abraham,² M. Maurer,³ J. Nativi-Nicolau.¹
Indefinite Survival of Fully MHC-Mismatched Murine Cardiac Allografts by Combination of Anti-BTLA mAb (6B2) and Anti-PD-1 mAb (PIM-2).

E. Yin,^1,2 M. Uchiyama,^1,3 X. Jin,^1,4 T. Shimokawa,³ H. Yagita,⁵ M. Niimi.¹
Indirect Allo-Antigen Stimulation Identifies the Presence of Either Regulatory IL-10 or of Effector Cytokines IFN-g, IL-21, IL-17a Production by Human Blood Allo-Reactive Memory T_FH and T_CONV CD4⁺ T Cells.

C. Macedo, F. Paul, Y. Masaki, H. Kevin, M. Diana.
Induction Agent Use and Outcomes in Older KT Recipients: Patient and Center Level Associations.

M. McAdams-DeMarco, Q. Huang, X. Luo, B. Orandi, S. Dorry.
Induction Immunosuppression and Post-Transplant Outcomes in Kidney Recipients with Hepatitis C Virus.

S. Bae, C. Durand, L. Kucirka, A. Massie, D. Segev.
Induction Therapy in Low Risk African American Kidney Transplant Recipients: Donor Factors.

F. Al Ammary,¹ S. Bae,¹ A. Massie,¹ N. Dagher,¹ E. King,¹ A. Wiseman,² D. Segev.¹
Induction Therapy with Depleting Antibodies in Low Immunological Risk Renal Transplant Patients Treated with a Steroid Free Regimen – Comparison of Alemtuzumab vs. Antithymocyte Globulin.

N. Bossini,¹ S. Sandrini,¹ R. Tardanico,² F. Valerio,¹ G. Setti,¹ C. Salviani,¹ S. Possenti,¹ P. Foini,¹ E. Marta,¹ G. Cancarini.¹
Induction Therapy with Rabbit Antithymocyte Globulin (rATG, Thymoglobulin^®) vs Basiliximab After Kidney Transplantation: A Health Economic Analysis from a German Perspective.

L. Cremaschi,¹ R. Thissen,² T. Benzing,² M. Wiesener,³ N. Zink,³ T. Paivanas,⁴ J. Reitan,⁴ M. Gallagher,⁵ F. Thaiss.¹
Induction with T-cell Depletional Agents Is Safe and Efficacious in the Very Elderly Kidney Transplant Recipients: An Analysis of the OPTN Database.

H. Dave, L. Wolfe, H. Fattah, D. Kumar, A. King, M. Levy, A. Cotterell, A. Sharma, C. Bhati, G. Gupta.
Ineligible: Attitudes and Follow-Up of Individuals Ruled Out of Living Kidney Donation.

D. Dobosz,¹ C. Thiessen,¹ J. Gannon,¹ S. Li,¹ K. Kennedy,² D. Gray,³ A. Mussell,³ E. Gordon,² S. Kulkarni,¹ P. Reese.³
Infection-Related Mortality After Kidney Transplantation in the Current Era.

I. Helanterä,¹ S. Kinnunen,² P. Karhapää,² A. Juutilainen,² P. Finne.³
Infections in De Novo Kidney Transplant Recipients Treated with the RANKL Inhibitor Denosumab: A Post-Hoc Analysis of the POSTOP Clinical Trial (NCT01377467).

M. Bonani,¹ D. Frey,² J. Brockmann,³ T. Fehr,¹ T. Müller,¹ N. Graf,⁴ R. Wüthrich.¹
Infectious Complication in Extremely Elderly Kidney Transplant (KT) Recipients: A Leading Cause of Death.

J. Cabrera,^1,3 M. Fernández-Ruiz,² M. Molina,¹ E. González,¹ N. Polanco,¹ F. López-Medrano,² J. Aguado,² M. Praga,¹ A. Andrés.¹
Inferior Outcomes in Hepatitis C Virus Positive Donors to Hepatitis C Virus Negative Kidney Recipients: Analysis of National Data.

H. Fattah, L. Kang, H. Dave, D. Kumar, A. King, C. Bhati, A. Sharma, G. Gupta.
Inflammation Amplifier, a Chemokine Inducer in Non-Immune Cells in Kidney Transplantation Graft.

H. Higuchi,^1,2 H. Bando,² J. Jing-Jing,² T. Atsumi,² D. Iwami,¹ K. Morita,¹ N. Shinohara,¹ M. Murakami.²
Inflammatory Conditions Switch the Effect of MSC on B Cells from Pro-Tolerogenic to Anti-Proliferative.

M. Franquesa,^1,2 F. Luk,¹ S. Korevaar,¹ L. Boon,³ F. Borras,² M. Betjes,¹ C. Baan,¹ M. Hoogduijn.¹
Influence of AKIN Stage on the Outcome of Deceased Donor Kidney Transplantation (DDKTx).

I. Qaqish, D. Haakinson, K. Reddy, M. Smith, H. Khamash, H. Raymond.
Influence of Cold Ischemia Time in Kidney Transplants from Small Pediatric Donors.

L. Kayler,¹ M. Lubetzky,² P. Friedman.³
Influence of Country-Associated Geographical Variables in the Ouctomes of Kidney Transplantation in Patients with HIV-Infection.

M. Cristelli,¹ F. Cofán,² H. Tedesco-Silva,¹ J. Trullas,³ D. Santos,¹ C. Manzardo,⁴ F. Aguero,⁴ A. Moreno,⁴ F. Oppenheimer,² F. Dieckmann,¹ J. Miro,⁴ J. Medina-Pestana.¹
Influence of Donor and Recipient CYP3A4, CYP3A5 and ABCB1 Genotypes on Outcomes in Liver Transplants.

M. Debette-Gratien,¹ J. Woillard,² N. Picard,² M. Sebbagh,⁴ D. Sautereau,⁵ V. Loustaud-Ratti,¹ D. Samuel,³ P. Marquet.²
Influence of Inclusion of the Liver on the Outcome After Intestinal Transplantation.

E. Canovai,¹ D. Monbaliu,¹ I. Jochmans,¹ M. Sainz Barriga,¹ L. Ceulemans,¹ G. De Hertogh,² J. Pirenne.¹
Influence of Lipid Levels on Cardiovascular Events After Early Conversion from Calcineurin Inhibitor to Everolimus: 24 M Analysis of the ELEVATE Study.

M. van der Giet,¹ J. de Fijter,¹ F. Oppenheimer,¹ L. Toselli,¹ G. Russ,¹ P. Lopez,² J. Aguilar,² P. Bernhardt,² Z. Wang,³ J. Cruzado,¹ H. Holdaas.¹
Influence of Pancreas Import and Cold Ischemia on Outcomes Following Pancreas Transplantation.

M. Khan,¹ H. El-Hennawy,¹ J. Rogers,¹ A. Farney,¹ G. Orlando,¹ A. Reeves-Daniel,² A. Palanisamy,² R. Stratta.¹
Influence of the Tacrolimus Metabolism Rate on BKV Infection After Kidney Transplantation.

G. Thölking,¹ C. Schmidt,¹ K. Schuette-Nuetgen,¹ D. Pabst,¹ R. Koch,² H. Wolters,³ S. Reuter,¹ B. Suwelack.¹
Informing Informed Consent for High KDPI Kidneys.

A. Nishio Lucar, D. Keith, G. Vranic.
Inhibitory FcγRIIB Functionally Inhibits Donor-Reactive CD8⁺ Memory T Cell Responses Following Transplantation.

D. Pinelli, M. Wagener, D. Liu, I. Badell, M. Ford.
Initial Evaluation of Use of NAT in Assignment of CMV and EBV Infection Status in Children Awaiting Solid Organ Transplant.

C. Burton, Y. Tong, J. Preiksaitis.
Initial Experience Treating Hepatitis C Positive Kidney Transplant Recipients with Non-Interferon-Containing Regimens: Successes and Challenges.

M. Aull, A. Watkins, J. Kim, K. Rhee, D. Dadhania, J. Lee, S. Kapur.
Initial Experience with Donor Specific Tregs in Kidney Transplantation.

J. Markmann,¹ E. Guinan,² E. Geissler,³ G. Cole,² S. Germana,¹ J. Kim,¹ B. Sawitzki.⁴
Initial Experience with Ledipasvir-Sofosbuvir Based Therapy for Recurrent Hepatitis C After Liver Transplantation.

A. Weick, O. Sadiq, S.-M. Jafri, D. Moonka.
Initial Experience with the Bacterial Enzyme IdeS® (IgG Endopeptidase) for Desensitization of Highly-HLA Sensitized (HS) Patients.

S. Jordan,¹ J. Choi,¹ X. Zhang,¹ M. Haas,² A. Peng,¹ J. Kahwaji,¹ R. Villicana,¹ A. Vo.¹
Injurious Procoagulant Pathways During Prolonged Cold Storage of the Donor Pancreas.

B. Sandhu, S. Charitidou, N. Vallant, A. McLean, D. Taube, P. DiCocco, P. Herbert, J. Crane, V. Papalois.
iNKT Cell Activation Under Co-Stimulatory Blockade Establishes Mixed Chimerism Through Thymic Regulatory T Cell Activation.

T. Hirai,¹ Y. Ishii,² R. Ishii,¹ S. Miyairi,¹ M. Ikemiyagi,¹ M. Okumi,¹ K. Tanabe.¹
iNKT Cell Ligands Administered with Bone Marrow Cells Expand Allo-Specific Regulatory T Cells In Vivo and Establish Transplant Tolerance.

S. Miyairi,^1,2 T. Hirai,¹ M. Okumi,¹ Y. Ishii,³ K. Yamazaki,² K. Tanabe.¹
Innate Immune Signaling During Ischemia-Reperfusion Injury in Human Orthotopic Liver Transplantation.

R. Sosa,¹ A. Zarrinpar,² C. Lassman,¹ R. Busuttil,² D. Gjertson,¹ J. Kupiec-Weglinski,¹ E. Reed.¹
Innate Lymphoid Cells Play a Key Role in Controlling Antimicrobial Defense in Intestinal Transplant Recipients.

J. Kaiser, C. Cosentino, A. Shukla, C. Desai, R. Girlanda, J. Hawksworth, C. Matsumoto, M. Zasloff, T. Fishbein, A. Kroemer.
Insights into the Treatment of Post-Transplant Focal Glomerulosclerosis: Experience Gained from a Concise Diagnostic and Management Protocol.

K. Koutroutsos,¹ R. Charif,¹ L. Moran,² J. Moss,² T. Cook,² C. Roufosse,² D. Taube,¹ M. Loucaidou.¹
Integrative, Multi-Cohort Analysis of Epstein-Barr Virus (EBV)-Positive and Negative Tumor Samples to Identify Gene-Signatures Associated with EBV Oncogenesis.

E. Maloney, E. Bongen, F. Vallania, N. Kotecha, P. Khatri, O. Martinez.
Interaction Between Kidney Tissue Proteome and Humoral Immunity in Antibody Mediated Rejection.

A. Konvalinka,¹ A. Chruscinski,² S. Kim,¹ K. Tinckam,¹ I. Jurisica,³ R. John.⁴
Intervention Development for the Allocation System Changes for Equity in kidNey Transplantation (ASCENT) Study.

K. Smith,¹ J. Gander,¹ M. Basu,¹ S. Pastan,¹ S. Mohan,² C. Escoffery,¹ L. Plantinga,¹ S. Kalloo,² G. Green,³ A. Berlin,⁴ G. Renville,⁵ T. Browne,⁶ N. Turgeon,¹ S. Caponi,⁷ J. Krisher,⁸ R. Patzer.¹
Intestinal Retransplantation in Children: Single Center Experience.

N. Celik,¹ F. Vyas,¹ G. Bond,¹ K. Soltys,¹ J. Rudolph,² R. Sindhi,¹ G. Mazariegos.¹
Intra-Operative Hepatic Arterial Flow Predicts Hepatic Artery Complications After Deceased Donor Liver Transplantation.

H. Fernandez, G. Testa, G. Klintmalm, P. Kim.
Intracellular OPN Is an Essential Protective Factor for Cardiac Endothelial Cell and the Long Term Heart Graft Survival.

Y. Su,^1,2,3 Z.-X. Zhang,^1,2,3 Z.-Q. Yin,¹ X.-Y. Huang,¹ A. Jevnikar.^1,2,3,4
Intragraft Molecular Pathways Associated with Tolerance Induction in Renal Transplantation.

L. Gallon,¹ J. Leventhal,¹ C. Dumur,² J. Mathew,¹ L. Nadimpalli,¹ A. Shetty,¹ S. Ildstad,³ V. Mas.²
Intraoperative Blood Loss Is a Promoter of Early Tumor Recurrence in Liver Transplant Patients with High Risk Hepatocellular Carcinoma.

A. Kornberg,¹ U. Witt,¹ J. Kornberg,² H. Friess,¹ K. Müller,³ K. Thrum.⁴
Intravenous Immunoglobulins Failed to Prevent Acute Antibody-Mediated Rejection in Kidney Transplant Recipients with De Novo DSA within the First Year After Transplant.

M. Matignon,¹ C. Pilon,² M. Commereuc,¹ C. Grondin,² T. Kofman,¹ P. Lang,¹ F. Canoui Poitrine,³ J. Cohen,² P. Grimbert.¹
Introducing a Mobile Phone Application to Transplant Patients to Encourage Medication Compliance and Education in This At-Risk Cohort.

A. Zanetti Yabur, A. Rizzo, J. Graham, J. Rocca.
Investigating Geographic Variation in the Number of Deceased Donor Transplants Performed in the U.S.

R. Carrico, D. Stewart, R. Ehrensberger, B. Shepard, D. Klassen.
Investigating Posttransplant Allo-Donor Specific CD57⁺ Cells in Patients with Alemtuzumab Induction and Belatacept-Based Regimen.

H. Xu, F. Feng, A. Kirk.
Is C3d-fixing Donor Specific HLA Antibody Detection Really Necessary?

P. Malvezzi,¹ M. Villemaire,¹ A. Bourdin,² T. Jouve,¹ R. Tetaz,¹ B. Janbon,¹ N. Terrier,³ D. Masson.²
Is CMV Prophylaxis Effective in CMV-Seropositive Patients Receiving Thymoglobulin as Induction Therapy?

E. Feitosa, F. Agena, J. Reusing Jr, F. Lemos, E. David-Neto.
Is Delayed Graft Function in Simultaneous Kidney-Pancreas Transplant Recipients Associated with an Increased Risk of Pancreas Graft Failure?

S. Singh,^1,2 S. Kim.^1,2,3,4
Is Donor Methamphetamine Use a Contraindication in Heart Transplantation?

M. Kittleson, J. Patel, L. Czer, A. Velleca, T. Aintablian, D. Chang, F. Esmailian, J. Kobashigawa.
Is Early Endoscopic Retrograde Cholangiopancreatography (ERCP) Safe Post Liver Transplant?

B. Wolk,¹ A. Shiani,² S. Lipka,² A. Kumar,² N. Kemmer,¹ H. Pinkas,² A. Alsina,¹ P. Brady,² A. Turner.¹
Is Facilitated Pancreas Allocation Effective?

R. Carrico,¹ J. Fridell,² J. Odorico,³ S. Niederhaus.⁴
Is It Worth Risking Lives of Multiple Procurement Surgeons to Save One Life in Extreme Weather Conditions?

H. Sharma, I. Al-Hasan, M. Richard, O. Ali, A. Sener, D. Quan, V. Macillister.
Is Ketorolac Really Safe for Donor Nephrectomy?

K. Takahashi, K. Putchakayala, L. Malinzak, J. Denny, M. Abouljoud, D. Kim.
Is MELD Score a Significant Predictor of Post-Transplant Mortality? An Old Issue with Simple Answer.

A. Rahnemai-Azar,¹ J. Perkins,¹ M. Montenovo,¹ S. Rayhill,¹ R. Bakthavatsalam,¹ N. Leca,² C. Blosser,² I. Di Castro,² R. Bhattacharya,³ J. Reyes,¹ L. Sibulesky.¹
Is Pretransplant Determination of Hepatocellular Carcinoma Tumor Grade Using Needle Biopsy Reliable for Transplant Candidate Selection? Analysis of 217 Liver Transplant Recipients.

C. Court, M. Harlander-Locke, D. Markovic, F. Kaldas, A. Zarrinpar, D. Farmer, S. Sho, J. Tomlinson, J. Hiatt, R. Busuttil, V. Agopian, D. Lu, S. Raman.
Is Prolonged Cold Ischemia a Contraindication to Using Kidneys from Acute Kidney Injury Donors?

M. Khan,¹ A. Carrier,¹ H. El-Hennawy,¹ A. Farney,¹ J. Rogers,¹ G. Orlando,¹ A. Reeves-Daniel,² A. Palanisamy,² M. Gautreaux,³ S. Iskandar,³ W. Doares,⁴ S. Kaczmorski,⁴ R. Stratta.¹
Is SVR Associated with Improved Hepatic Function in Hepatitis C Gen 1 Pts with Cirrhosis 1 Year After Completing Treatment with Sofosbuvir + Simeprevir +/- Ribavirin?

A. Modi,¹ J. Hermann,¹ H. Nazario,² S. Gonzalez,¹ J. Gripshover,³ M. Gautam,¹ J. Weinstein,² D. Potosky,³ M. Barnes,² A. Habib,² P. Mantry,² J. Trotter.¹
Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?

T. Zens, G. Leverson, R. Redfield, P. Chlebeck, L. Zitur, D. Kaufman, L. Fernandez.
Is There a Link Between Proteinuria and Increased FGF-23 Levels in Renal Transplant Patients.

E. Tutal,¹ S. Sezer,¹ Z. Bal,¹ B. Demirci,¹ M. Haberal.²
Ischemia Reperfusion Induced Murine Heart Transplant Rejection Is Complement Dependent.

N. Chun,¹ M. Zhang,² R. Fairchild,³ P. Heeger.¹
Ischemia-Reperfusion Injury Following Transplantation: Implications for the Modulation of CXCL8 Chemokine Function.

B. Martinez Burgo,¹ S. Ali,¹ J. Kirby,¹ N. Sheerin,¹ S. Cobb,² D. Kashanin.³
Isolating High Islet Mass Even from Alcoholic Pancreatitis Pancreases Intended for Clinical Islet Auto-Transplantation: Improved Strategies to Human Islet Isolation Technique.

A. Balamurugan, G. Loganathan, B. Tweed, W. Tucker, S. Mokshagundam, S. Williams, M. Hughes.
IVIG and High Dose Steroid Treatment of Transplant Glomerulopathy Effectively Slows Progression of Loss of Renal Allograft Function.

K. Sablik,¹ C. Looman,² M. Clahsen-van Groningen,³ J. Damman,³ D. Roelen,⁴ M. van Agteren,¹ M. Betjes.¹